Calvet, J.; Gratacós, J.; Amengual, M.J.; Llop, M.; Navarro, M.; Moreno, A.; Berenguer-Llergo, A.; Serrano, A.; Orellana, C.; Cervantes, M.
CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study. Viruses 2020, 12, 1277.
https://doi.org/10.3390/v12111277
AMA Style
Calvet J, Gratacós J, Amengual MJ, Llop M, Navarro M, Moreno A, Berenguer-Llergo A, Serrano A, Orellana C, Cervantes M.
CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study. Viruses. 2020; 12(11):1277.
https://doi.org/10.3390/v12111277
Chicago/Turabian Style
Calvet, Joan, Jordi Gratacós, María José Amengual, Maria Llop, Marta Navarro, Amàlia Moreno, Antoni Berenguer-Llergo, Alejandra Serrano, Cristóbal Orellana, and Manel Cervantes.
2020. "CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study" Viruses 12, no. 11: 1277.
https://doi.org/10.3390/v12111277
APA Style
Calvet, J., Gratacós, J., Amengual, M. J., Llop, M., Navarro, M., Moreno, A., Berenguer-Llergo, A., Serrano, A., Orellana, C., & Cervantes, M.
(2020). CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study. Viruses, 12(11), 1277.
https://doi.org/10.3390/v12111277